Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Immatics ( (IMTX) ) has issued an announcement.
Immatics N.V. announced that Bristol Myers Squibb has decided to terminate their collaboration agreements related to allogeneic programs and a specific target under a multi-target TCR-T collaboration. Despite the termination effective March 12, 2025, Immatics will retain the upfront payments received, while their 2019 strategic collaboration with BMS remains intact, potentially affecting their strategic positioning and future operations.
More about Immatics
Immatics N.V. operates in the biotechnology industry, focusing on the development of T-cell receptor-based therapies for cancer treatment. The company’s primary products include allogeneic programs and multi-target TCR-T strategies, with significant collaborations in place with major pharmaceutical companies.
YTD Price Performance: -29.63%
Average Trading Volume: 614,241
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $884.4M
See more insights into IMTX stock on TipRanks’ Stock Analysis page.
